181 related articles for article (PubMed ID: 30269036)
1. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
Podshivalova K; Wang EA; Hart T; Salomon DR
Leuk Res; 2018 Nov; 74():1-9. PubMed ID: 30269036
[TBL] [Abstract][Full Text] [Related]
2. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.
Ling Z; Fang ZG; Wu JY; Liu JJ
Kaohsiung J Med Sci; 2021 May; 37(5):392-401. PubMed ID: 33615686
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.
Li H; Kong X; Cui G; Ren C; Fan S; Sun L; Zhang Y; Cao R; Li Y; Zhou J
Int J Hematol; 2015 Nov; 102(5):558-68. PubMed ID: 26362858
[TBL] [Abstract][Full Text] [Related]
4. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
5. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
6. Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells.
Xu W; Wang X; Tu Y; Masaki H; Tanaka S; Onda K; Sugiyama K; Yamada H; Hirano T
Chem Biol Interact; 2019 Sep; 310():108726. PubMed ID: 31255635
[TBL] [Abstract][Full Text] [Related]
7. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
Wu KN; Zhao YM; He Y; Wang BS; Du KL; Fu S; Hu KM; Zhang LF; Liu LZ; Hu YX; Wang YJ; Huang H
Leuk Lymphoma; 2014 Mar; 55(3):668-76. PubMed ID: 23741975
[TBL] [Abstract][Full Text] [Related]
9. microRNA-452 exerts growth-suppressive activity against T-cell acute lymphoblastic leukemia.
Wang H; Guo Q; Zhu G; Zhu S; Yang P; Zhang M
J Investig Med; 2018 Apr; 66(4):773-779. PubMed ID: 29326345
[TBL] [Abstract][Full Text] [Related]
10. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
11. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
12. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
13. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
14. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.
Kumar V; Palermo R; Talora C; Campese AF; Checquolo S; Bellavia D; Tottone L; Testa G; Miele E; Indraccolo S; Amadori A; Ferretti E; Gulino A; Vacca A; Screpanti I
Leukemia; 2014 Dec; 28(12):2324-35. PubMed ID: 24727676
[TBL] [Abstract][Full Text] [Related]
15. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20.
Liu Z; Smith KR; Khong HT; Huang J; Ahn EE; Zhou M; Tan M
Oncotarget; 2016 Nov; 7(48):78667-78679. PubMed ID: 27637078
[TBL] [Abstract][Full Text] [Related]
16. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways.
Li XJ; Luo XQ; Han BW; Duan FT; Wei PP; Chen YQ
Br J Cancer; 2013 Oct; 109(8):2189-98. PubMed ID: 24030073
[TBL] [Abstract][Full Text] [Related]
18. [Synergistic cytotoxic effects of rapamycin and idarubicin on human acute T-cell lymphoblastic leukemia Jurkat cells].
Zhao YM; Wu KN; Wang YJ; Wu GQ; Cao WJ; Yu XH; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 40(5):482-8. PubMed ID: 21984149
[TBL] [Abstract][Full Text] [Related]
19. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract][Full Text] [Related]
20. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
Correia NC; Melão A; Póvoa V; Sarmento L; Gómez de Cedrón M; Malumbres M; Enguita FJ; Barata JT
Oncotarget; 2016 Feb; 7(7):8268-81. PubMed ID: 26882564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
